172093-34-4

Upstream product

• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 
• 107-08-4 1-iodo-propane 
• 106-94-5 propyl bromide 
• 65-49-6 4-Aminosalicylic acid 
• 4136-97-4 methyl 4-aminosalicylate 

Downstream Products

• 2486-79-5 4-amino-2-propoxy-benzoic acid 
• 172093-35-5 methyl 4-(acetylamino)-5-chloro-2-(n-propoxy)benzoate 
• 1028126-99-9 C₁₃H₁₆N₂O₆ 
• 1388193-72-3 C₁₃H₁₆BrNO₄ 
• 1388193-74-5 C₁₀H₁₂BrNO₃ 
• 1388193-83-6 C₁₂H₁₅Br₂NO₃ 
• 1388193-71-2 C₁₂H₁₅BrClNO₃ 
• 1388193-76-7 C₁₃H₁₇BrClNO₃ 
• 1388193-85-8 C₁₃H₁₇Br₂NO₃ 
• 1388193-53-0 Br^(1-)*C₃₂H₃₆ClN₂O₇⁽¹⁺⁾ 
• 1388193-56-3 Br^(1-)*C₃₃H₃₈ClN₂O₇⁽¹⁺⁾ 
• 1388193-63-2 Br^(1-)*C₃₂H₃₆BrN₂O₇⁽¹⁺⁾ 
• 1388193-65-4 Br^(1-)*C₃₃H₃₈BrN₂O₇⁽¹⁺⁾ 
• 172093-36-6 4-amino-5-chloro-2-(n-propoxy)benzoic acid 

Relevant academic research and scientific papers

Synthesis and biological evaluation of berberine derivatives as IBS modulator

Irritable bowel syndrome is the most common functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort in association with a change in bowel habit. 5-HT receptor modulators have been developed as IBS therapeutic agents and proved to be effective in the treatment of the disease. In this letter, 12 berberine derivatives were designed and synthesized as 5-HT receptor modulators. Preliminary biological tests suggested that the new compounds exhibited promising activity for IBS therapy.

Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors

A series of hydrophobic p-aminosalicylic acid derivatives containing a lipophilic side chain at C-2 and an amino or guanidine at C-5 were synthesized and evaluated for their ability to inhibit neuraminidase (NA) of influenza A virus (H3N2). All compounds were synthesized in good yields starting from commercially available p-aminosalicylic acid (PAS) using a suitable synthetic strategy. These compounds showed potent inhibitory activity against influenza A NA. Within this series, six compounds, 11, 12, 13e, 16e, 17c, and 18e, have the good potency (IC50 = 0.032-0.049 μM), which are compared to Oseltamivir (IC50 = 0.021 μM) and could be used as lead compounds in the future.

Development of potent serotonin-3 (5-HT3) receptor antagonists. I. Structure-activity relationships of 2-alkoxy-4-amino-5-chlorobenzamide derivatives

A new series of 2-alkoxy-4-amino-5-chlorobenzamide derivatives hearing five- to seven-membered heteroalicyclic rings in the amine moiety was synthesized and evaluated for serotonin-3 (5-HT3) receptor antagonistic activity by assaying the ability to antagonize the yon Bezold-Jarisch reflex in rats. The five- to seven-membered heteroalicycles comprise pyrrolidine, morpholine, 1,4-thiazine, piperidine, piperazine, 1,4-oxazepine, 1,4- thiazepine, azepine, and 1,4-diazepine rings. Among them, some benzamide derivatives having a 1,4-diazepine ring showed a potent 5-HT3 receptor antagonistic activity. In particular, 4-amino-5-chloro-N-(1,4- dimethylhexahydro-1H-1,4-diazepin-6-yl)-2-ethoxyhenzamide (96) and the 1- benzyl-4-methylhexahydro-1H-1,4-diazepine analogue 103 showed potent 5-HT3 receptor antagonistic activity without 5-HT4 receptor binding affinity.